Eli Lilly has stopped disclosing its early-stage pipeline and most deal values as it grows larger. An analysis of why the drugmaker's rising secrecy erodes trust.
Eli Lilly is getting more opaque as it gets bigger.
Earlier this year, the drugmaker stopped disclosing its early-stage pipeline work. Its Phase 1 projects …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Healthy Returns: Eli Lilly makes a new push into vaccines — here’s what to know
Eli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areas
NewLimit’s $435M megaround; Lilly’s busy dealmaking week
Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals
Lilly dives into vaccine research with 3 biotech buyouts
Legend Biotech emerged as a rare market winner
An insider’s look at LillyDirect
Eli Lilly announces acquisition of 3 vaccine makers in $4 billion deal - UPI.com
Lilly, Ascidian link up in RNA exon editing pact
Five biotech news updates to stay on top of today
Club name Eli Lilly made its third deal of the year to acquire an attractive experimental drug.
Leerink Partners sees shares of Eli Lilly adding another 19% from here.
The drugmaker announced it will buy three privately held vaccine makers in deals worth almost $4 billion combined.
Eli Lilly's new top dealmaker explains how the company changed its approach to M&A now that it's the most valuable pharmaceutical…
A new set of lists ranks drug company laboratories on two criteria: innovation and invention.
The company's stock has zoomed this year, driven by the explosive growth of the weight-loss drug market.
